期刊
NEURO-ONCOLOGY
卷 14, 期 7, 页码 819-829出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nos117
关键词
AKT; glioblastoma; GBM; mTOR; PI3K
资金
- Novartis Pharmaceuticals
- Amgen
- Astra Zeneca
- Boehringer
- Esai
- Novartis
- Genentech/Roche
- Genzyme
- Medimmune
- Merck
- Vascular Biogenics
- Exelixis
- Sanofi-Aventis
- Plexxikon
Glioblastoma (GBM) is the most common and lethal primary malignant tumor of the central nervous system, and effective therapeutic options are lacking. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in many human cancers, including GBM. Agents inhibiting PI3K and its effectors have demonstrated preliminary activity in various tumor types and have the potential to change the clinical treatment landscape of patients with solid tumors. In this review, we describe the activation of the PI3K pathway in GBM, explore why inhibition of this pathway may be a compelling therapeutic target for this disease, and provide an update of the data on PI3K inhibitors in clinical trials and from earlier investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据